Small molecules that block STAT3 in triple-negative breast cancer
Mechanistic studies of hirsutinolides and azetidine-based small molecule inhibitors of STAT3
['FUNDING_R01'] · CEDARS-SINAI MEDICAL CENTER · NIH-11307129
New small-molecule drugs aim to block STAT3 and antioxidant defenses to kill triple-negative breast cancer cells.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CEDARS-SINAI MEDICAL CENTER (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-11307129 on ClinicalTrials.gov |
What this research studies
This project develops two types of small molecules — natural-product hirsutinolides (R001/R002) and synthetic azetidine-based compounds (H182/H333) — to disrupt STAT3 signaling and related antioxidant enzymes that help tumors survive. The team tests these compounds in triple-negative breast cancer cells and mouse tumor models, uses RNA sequencing to track gene activity changes, and measures reactive oxygen species, DNA damage, and tumor responses. Their approach seeks to lower G6PD and TrxR1 activity, reduce glutathione levels, and trigger cancer cell death. Researchers compare the different compounds to identify which most effectively slows tumor growth with acceptable safety.
Who could benefit from this research
Good fit: People with triple-negative breast cancer, especially those with relapsed or chemotherapy-resistant tumors, would be the most likely candidates for future trials.
Not a fit: Patients with other types of breast cancer or whose tumors do not rely on STAT3 or the studied antioxidant pathways may not benefit from these treatments.
Why it matters
Potential benefit: If successful, this work could identify new drug candidates that shrink or stop growth of chemotherapy-resistant triple-negative breast cancers.
How similar studies have performed: Similar strategies targeting STAT3 and tumor redox balance have shown encouraging results in preclinical models but are not yet proven therapies for patients.
Where this research is happening
LOS ANGELES, UNITED STATES
- CEDARS-SINAI MEDICAL CENTER — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TURKSON, JAMES K — CEDARS-SINAI MEDICAL CENTER
- Study coordinator: TURKSON, JAMES K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer Cell, Breast Cancer Model, Breast Cancer Treatment